Don’t Take Opioids Off the Market. Make It Harder to Abuse Them.

When the opioid crisis enters the room, subtlety often leaves through the nearest window. People hear the word opioid and understandably think of overdose headlines, devastated families, and a healthcare system that has spent years trying to mop up a flood with a paper towel. In that emotional storm, one solution can sound satisfyingly simple: take opioids off the market. Problem solved. Curtain down. Cue applause.

Except real life is rude like that. Opioids still have a legitimate medical role. They remain important for some cases of severe acute pain, cancer-related pain, palliative care, post-surgical recovery, and select chronic pain situations where benefits outweigh risks and patients are monitored carefully. Removing them entirely would not just target misuse. It would also hit patients who use these medicines exactly as prescribed and rely on them to function, sleep, move, or recover after serious illness or injury.

So the smarter argument is not “ban the medicine.” It is “design the system so abuse becomes harder, risk becomes easier to spot, treatment becomes easier to access, and pain care becomes more intelligent.” In other words, do not burn down the pharmacy because the locks need upgrading.

Why Opioids Cannot Simply Vanish

There is a reason major U.S. health agencies and medical guidance do not say opioids should disappear from medicine altogether. Pain is not one-size-fits-all. Some patients do well with nonopioid options such as acetaminophen, NSAIDs, physical therapy, exercise, cognitive behavioral therapy, or certain antidepressants and anticonvulsants. For many common acute pain problems, those tools can work as well as or better than opioids. That is a major point, and it deserves emphasis.

But many is not the same as all. Severe trauma, major surgery, advanced cancer, end-of-life care, and certain complex pain conditions can require opioids as part of a larger treatment plan. A flat ban would treat a teenager after wisdom-tooth surgery, a patient with metastatic cancer, and a person misusing diverted pills as if they were the same story. They are not.

Healthcare policy gets into trouble when it mistakes bluntness for strength. A hammer is powerful, sure. It is also a terrible instrument for threading a needle, frosting a cake, or performing medicine.

The Difference Between Access and Easy Misuse

The real problem is not that opioids exist. The problem is that for too long, the system made them too easy to overprescribe, too easy to misuse, too easy to divert, and too hard to track. Add inconsistent pain care, patchy insurance coverage for safer alternatives, uneven addiction treatment access, and a rapidly evolving illicit drug supply, and you have a public health mess with layers.

That matters because today’s overdose crisis is not driven only by prescription bottles sitting in suburban medicine cabinets like tiny villains in orange plastic tuxedos. Illicitly manufactured fentanyl and other synthetic opioids now dominate a large share of overdose deaths. That means a policy focused only on removing legal prescription opioids can miss the bigger battlefield.

The Better Goal: Keep Legitimate Pain Relief, Reduce Abuse Potential

If the mission is to protect patients and reduce overdose deaths, the answer is not disappearance. The answer is friction. Smart, targeted, evidence-informed friction. Make misuse harder. Make diversion riskier. Make reckless prescribing less likely. Make rescue and treatment easier to reach. That is the lane.

What “Abuse-Deterrent” Really Means

Abuse-deterrent opioid formulations are designed to make common forms of manipulation more difficult or less attractive. Some use physical or chemical barriers. Some combine an opioid with an antagonist that becomes active if the product is tampered with. Others are engineered to resist certain forms of manipulation or delivery that can intensify harm.

Important reality check: abuse-deterrent does not mean abuse-proof. It is not a magic force field. It does not eliminate addiction risk. It does not stop someone from swallowing too many intact pills. And it definitely does not replace careful prescribing, patient education, or treatment for opioid use disorder.

Still, that does not make abuse-deterrent technology pointless. It means it should be treated like a seat belt rather than an invisibility cloak. Seat belts do not prevent every crash, but nobody argues that therefore cars should come without them.

What the Evidence Suggests

Research and policy reviews have shown that reformulated abuse-deterrent products can reduce abuse of specific opioid products. That is meaningful. At the same time, those benefits can be limited when people switch to other opioids or move to illicit drugs. So the lesson is not “abuse-deterrent formulations failed.” The lesson is “they help, but they cannot do the whole job alone.”

That nuance matters. Public policy loves tidy slogans. Biology and behavior do not. The most effective response is layered: safer product design, better prescribing, better monitoring, better treatment access, better overdose reversal access, and better nonopioid pain care.

Seven Smarter Ways to Make Opioids Harder to Abuse

1. Expand Abuse-Deterrent Formulations Without Pricing Patients Out

If abuse-deterrent technology reduces manipulation of specific products, the next step is obvious: make those formulations more available, not less. That includes encouraging innovation, faster development of affordable generics, and coverage policies that do not make safer versions feel like luxury items with a velvet rope.

A safer product that patients cannot afford is a public relations strategy, not a public health strategy. If policymakers want abuse-deterrent opioids to matter, insurers, regulators, manufacturers, and pharmacy benefit systems have to stop treating affordability like an optional side quest.

2. Prescribe Smaller Quantities and Reassess Early

Safer prescribing is not anti-patient. It is anti-carelessness. When opioids are needed for acute pain, the goal should be the lowest effective dose for the shortest appropriate duration, with follow-up rather than autopilot. A seven-day mountain of pills for a short-lived problem creates extra leftovers, and leftovers have a nasty habit of becoming someone else’s “borrowed” disaster.

Clinicians should also set functional goals, review risks, and talk plainly about side effects, sedation, dependence, and overdose. The prescription should come with a conversation, not just a stapled leaflet no one reads until the dog has already eaten half the packaging.

3. Use PDMPs Like They Matter Because They Do

Prescription drug monitoring programs, or PDMPs, are one of the least glamorous and most useful tools in this entire discussion. They help clinicians see controlled-substance prescription histories, identify overlapping prescriptions, spot risky patterns, and make safer decisions. In plain English, they help the healthcare system stop pretending it has no idea what is going on.

The next leap is better integration. If PDMPs live in a digital basement that requires fifteen passwords and a minor pilgrimage, busy clinicians will not use them as effectively as they could. If they are integrated into normal workflow, they become real prevention tools instead of bureaucratic wallpaper.

4. Pair Opioids With Naloxone When Risk Is Higher

Naloxone saves lives. Full stop. Wider access to naloxone, including over-the-counter availability, is one of the most practical harm-reduction wins in modern drug policy. Patients at higher overdose risk, including those on higher doses or taking other sedating medicines, should not leave the conversation without a plan for overdose reversal.

This should not be treated like an accusation. Providing naloxone is not saying, “We expect you to do something wrong.” It is saying, “Breathing is a hobby we would like you to keep.” Medicine uses backup plans all the time. This one just happens to be lifesaving.

5. Make Safe Storage and Disposal Boringly Routine

Unused pills in an unlocked drawer are not harmless. They are an invitation to diversion, experimentation, accidental ingestion, and family tragedy. Safe storage should be discussed as routinely as dosing instructions. Safe disposal should be just as ordinary.

Drug take-back programs and year-round disposal options matter because prevention often starts after the prescription is no longer needed. The easiest opioid to misuse is often the one that should have been thrown out three months ago.

6. Screen for Opioid Use Disorder and Treat It Early

No policy about opioid misuse is serious unless it includes treatment for opioid use disorder. That means real access to evidence-based medications such as buprenorphine, methadone, and naltrexone, along with counseling and recovery support when appropriate. Making abuse harder is valuable, but making treatment easier is essential.

Otherwise, policy becomes a hallway full of locked doors. If a patient is showing signs of misuse, dependence, or opioid use disorder, the response cannot be shame, panic, or abrupt abandonment. It should be assessment, support, treatment, and a plan that keeps the person alive.

7. Build Better Pain Care So Opioids Are Not the Default

The healthiest opioid policy may begin with a question that sounds almost annoyingly obvious: what if patients had better options before opioids became the automatic answer? Nonopioid medications, physical therapy, behavioral approaches, exercise therapy, interventional care, and selected complementary approaches can all play meaningful roles depending on the condition.

The challenge is that these options are often harder to access than a bottle of pills. They may require referrals, appointments, transportation, time off work, and insurance approvals that arrive with the urgency of a sleeping sloth. If policymakers want fewer people to depend on opioids, they have to fund and normalize alternatives instead of simply praising them from afar.

What Policymakers Must Avoid

Overcorrection is a real risk. After years of excessive prescribing, some systems swung so hard in the other direction that stable patients were suddenly cut off, rapidly tapered, or left to navigate pain with little support. That is not safety. That is chaos wearing a policy badge.

Good care requires individualized decisions. Abrupt discontinuation can harm patients, destabilize treatment, and erode trust. The best path is careful reassessment, shared decision-making, and a balanced plan that reduces risk without treating every patient like a suspect in a trench coat.

The Strongest Public Health Argument

If you remove opioids entirely from legitimate medicine, you do not eliminate pain. You just change where desperate people look for relief. Some will suffer in silence. Some will bounce from clinic to clinic. Some may turn to unsafe or illicit substitutes. That is not a victory. That is a policy own goal.

A better system accepts two truths at once. First, opioids carry serious risk and must be prescribed with far more discipline than in the past. Second, they still belong in medicine for some patients. Mature policy can hold both ideas without fainting on the courthouse steps.

That is why the most defensible position is this: keep opioids available for legitimate medical use, but redesign the environment around them. Push abuse-deterrent technology. Improve generic access. Tighten prescribing. Expand PDMP use. Co-prescribe or discuss naloxone when risk is elevated. Promote safe disposal. Build out nonopioid pain care. Treat opioid use disorder early and seriously. In short, make the dangerous path harder and the safe path easier.

That approach is less dramatic than a ban. It is also more humane, more realistic, and more likely to work. Public health is not a movie trailer. It does not need more explosions. It needs better systems.

Experiences From the Real World: Why This Debate Is Personal

Talk to a pain patient and the argument stops sounding abstract very quickly. One patient recovering from a major spinal procedure may tell you that opioids were not a luxury or a moral failing; they were the bridge that got them out of bed, into physical therapy, and eventually back to normal life. Without that bridge, recovery would not have looked noble or disciplined. It would have looked like missed rehab sessions, shallow breathing from pain, and weeks of unnecessary suffering. For that patient, the idea of pulling opioids off the market sounds less like reform and more like punishment for a crisis they did not create.

Now talk to a family physician. They may describe the opposite pressure: years of seeing patients arrive with overlapping prescriptions, poorly explained pain plans, and risks that were never discussed clearly enough. They may say the hardest part is not deciding whether opioids are good or bad. The hardest part is deciding who may truly benefit, who is at greater risk, and how to protect both without becoming either reckless or cruel. Most clinicians do not want a free-for-all, and they do not want a scorched-earth crackdown either. They want tools that make careful practice possible.

Pharmacists often see another side of the story. They are the last checkpoint before a medication reaches the patient, and sometimes the first to notice a pattern that does not feel right. A pharmacist may see a prescription that technically looks fine but raises practical questions: Is the dose unusually high for someone new to the drug? Is the patient taking another sedating medication? Has anyone talked with them about naloxone? In a better system, those questions are not awkward interruptions. They are built into the process, expected and respected.

Then there are families. A parent may say the issue started not with street drugs, but with leftover pills after a sports injury or dental procedure. A spouse may remember how quickly ordinary use turned into something frightening. A sibling may say the most devastating part was how long it took to get treatment once misuse had clearly become something more serious. These experiences are why disposal programs, safer packaging, better education, and easier access to treatment matter so much. Prevention often begins in places that seem boring until they become heartbreakingly important.

Emergency responders, meanwhile, tend to speak the language of urgency. They know naloxone matters because they have seen what happens when it is available and what happens when it is not. They know overdose reversal buys time, but only treatment and follow-up change the longer story. They also know that stigma is a terrible co-pilot. People do not ask for help when every door feels labeled with shame.

Put all of those experiences together and the policy answer becomes clearer. The point is not to defend careless opioid use. The point is to protect legitimate pain treatment while shrinking the opportunities for misuse and expanding the pathways to safety. Real people do not live inside slogans. They live inside bodies, families, clinics, and communities. That is exactly why the best answer is not to erase opioids from medicine. It is to make abuse far harder, rescue far easier, and treatment far more available.

Conclusion

“Take them off the market” sounds decisive. “Make them harder to abuse while protecting patients who truly need them” sounds less theatrical. But healthcare should not be graded on dramatic flair. It should be graded on whether patients are safer, pain is treated responsibly, and fewer families end up planning funerals.

Opioids should not get a free pass. They should get guardrails. Strong ones. Smart ones. Affordable ones. That is how medicine grows up after a crisis: not by pretending pain disappeared, but by refusing to make misuse easy ever again.